Prime Medicine
Prof. Czechowicz is a translationally oriented-physician scientist at Stanford University in the Department of Pediatrics Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine. She is also a member of the Stanford Institute of Stem Cell Biology and Regenerative Medicine. Dr. Czechowicz previously spent a decade on the Farm as a Stanford trainee completing her undergraduate, medical school and PhD degrees while conducting research with Prof. Irving Weissman. She subsequently did further clinical training in Boston, completing her residency in Pediatrics at Boston Children’s Hospital and pursued subspecialty training in Pediatric Hematology/Oncology at the Dana Farber Cancer Institute while simultaneously conducting postdoctoral research with Prof. Derrick Rossi in collaboration with Prof. David Scadden. Dr. Czechowicz’s research has focused around improving the utilization of hematopoietic stem cells for the treatment of diverse blood and immune diseases, and she has done pioneering work showing that hematopoietic stem cell depletion is a critical component to donor hematopoietic stem cell engraftment. Multiple pre-clinical and clinical therapies are in development based upon her studies aimed at the elimination of chemotherapy and irradiation from transplant protocols. Furthermore, Dr. Czechowicz’s clinical interests are in bone marrow failure syndromes with a particular interest in Fanconi Anemia and she has led several innovative cell and gene therapy trials attempting to improving outcomes for patients with this disease. Dr. Czechowicz is also quite passionate about mentoring and training future generations of physicians and scientists, and is very supportive of helping diverse trainees on various traditional and non-traditional career paths.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Prime Medicine
4 followers
Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Prime Editing searches to find the precise place in the genome to edit and replaces the segment of faulty DNA with a correct copy of DNA. A single Prime Editor can correct the individual mutations found across patients, meaning Prime Editing can potentially address more than 90 percent of known disease-causing genetic mutations. We envision a world where this technology can cure, halt, and ultimately prevent genetic diseases, providing lifelong benefit to patients. Prime Medicine offers the opportunity to shape the future of gene editing and transform how medicines are used to treat disease. Realizing the promise of Prime Editing requires a talented team with diversity of viewpoints and expertise. We’re building a group of dedicated, scientifically curious individuals who are passionate about helping patients live longer, healthier lives.